-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Phase 3 clinical trial CheckMate-816 evaluated the efficacy of Opdivo (nivolumab) in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) that could be removed before surgery.
the trial group received three doses of Opdivo plus chemotherapy before surgery.
results showed that Opdivo combined chemotherapy reached the primary endpoint of pathological complete remission (pCR), with a higher proportion of patients in the group receiving combination therapy not detecting tumor cells in surgically removed tissue than in the placebo treatment group.
CheckMate-816 means that Opdivo of BMS became the first immunotherapy in Phase 3 clinical trials, in combination with chemotherapy, to significantly improve the efficacy of patients with pre-surgery NSCLC removal.
CheckMate-816 is still in progress and will continue to evaluate another major endpoint of the trial, the time patients remain cancer-free or deteriorating, and other critical secondary endpoints.
: This means That Opdivo has beaten a number of competitors in the NSCLC's new complementary treatments, including Mercedon's PD-1 single-anti-Keytruda, Roche's PD-L1 single-anti-Tecentriq and AstraZenecom's PD-L1 single-anti-Imfinzi.
Although Opdivo has been approved for the treatment of metastasis NSCLC patients, earlier treatment may give it an advantage over Merck's Keytruda, which dominates the late NSCLC field.
.